Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 1997

View Archived Issues

StressGen and Genzyme announce closing of joint venture

PLC Systems faces class action suits

Pharmacia Biotech and Amersham Life Science merger finalized

Study confirms hepatitis B vaccine efficacy

GABA-based drug for anxiety enters phase I

PLC responds to nonapproval of its Heart Laser TMR System

New HRT option from Organon

Dietary changes may pose threat to patients on oral anticoagulants

Matrix and Savage enter marketing agreement for AccuSite

Medtronic's therapy for urinary incontinence recommended for approval by FDA panel

Update on Proleukin regulatory status; Photofrin approved in Germany

First approval for Elan's Diastat

SKB reports new agents for atherosclerosis

Protein kinase C inhibitors discovered at Cephalon

Theratechnologies: Q2 1997 highlights

Aquila issued patent covering potent drug delivery agents

Tacrine analogs reported for Alzheimer's disease

Antiarthritic activity of British Biotech MMP/TNF-alpha inhibitors

Vanadium compounds for treatment of diabetes

AmBisome approved in Korea

Cantab: Q2 1997 highlights

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...